此前一晚，公司发布公告，称公司独家经销的韩国Huons BioPharma Co., Ltd.（以下简称Huons BP）生产的注射用A型肉毒毒素（即通常所说的肉毒素）产品 在国内获批。这也成为公司战略布局的关键里程碑。 在中国医美市场上，肉毒素有"除皱神器"之称，是排名第二的非手术类医美项目，但《每日经济新闻》记者（以下简称每经记者）注意到，Huons BP的这款 产品是国内获批的第七款同类产品，且乐普医疗、华东医药、通化东宝等医药公司也在布局这一领域。 既然获批时间并不占据优势，肉毒素获批为何仍能带动公司股价上涨？在国产肉毒素因竞争激烈而走上降价之路时，后来者还有机会吗？ 1月9日开盘，爱美客（SZ300896，股价149.91元，总市值453.62亿元）股价一度大幅上扬，截至当天收盘上涨2.69%。 对于延期的原因，公司表示已于2024年7月收到国家药品监督管理局"注射用A型肉毒毒素"注册上市的《受理通知书》，目前正处于评审审批阶段，预计尚 需一定时间。 肉毒素产品进入红海，后来者市占率仅个位数 过去7年，国内肉毒素市场的竞争格局发生了巨大变化。数据显示，2018年时，市面上只有美国艾尔建的Botox（ ...

Core Viewpoint - The article discusses the upcoming Fourth China Plastic Surgery and Regenerative Medicine Development Conference and the 14th Beijing International Aesthetic Surgery Conference, scheduled for October 31 to November 2, 2025, in Beijing, aimed at promoting the development of plastic surgery and enhancing collaboration among related disciplines [2]. Event Overview - The conference will feature a main forum, an innovation transformation competition final, and nine sub-forums, with a total expected attendance of around 500 participants [5][6]. - The event is organized by the Chinese Academy of Medical Sciences Plastic Surgery Hospital and the Beijing Eight Great Places Aesthetic Medical Technology Group [4]. Main Forum Agenda - The main forum will include a welcome address, opening speeches, and a series of thematic presentations covering topics such as innovative medical technology, marketing integration in medical device commercialization, and advancements in skin chip technology [6][7]. - Notable speakers include representatives from various medical and technological institutions, discussing topics relevant to the plastic surgery and aesthetic medicine fields [6]. Innovation Competition - The third innovation transformation competition will focus on showcasing innovative achievements in plastic surgery and aesthetic medicine, covering areas such as materials, devices, and digital applications [7]. - The competition aims to connect projects with capital, facilitating the transition from research to clinical application [7]. Investment and Financing Forum - A dedicated forum on investment and financing in the aesthetic medicine sector will take place, featuring discussions on industry trends and opportunities from various investment professionals [10][11]. - The forum will include presentations on topics such as the current state of the aesthetic medicine industry and the development of domestic medical aesthetic equipment [10][11]. Additional Activities - The conference will also host product exhibitions and provide opportunities for networking among industry professionals, researchers, and investors [3][12]. - Various sub-forums will address topics like medical device safety, digital transformation in aesthetic medicine, and regenerative medicine [12][25][34].

Core Insights - The Korean medical beauty industry is experiencing significant growth, with a projected increase in foreign patients visiting for treatments, particularly from China and Japan [4][5][6] - The cancellation of the tax refund policy for foreign patients raises concerns about the attractiveness of Korea as a medical tourism destination [1][6] - The competitive pricing and advanced technology in Korean medical beauty services continue to draw consumers, especially from China [2][3][4] Group 1: Market Growth and Trends - In 2024, the number of foreign patients seeking medical treatment in Korea is expected to reach nearly 1.2 million, a 93.2% increase from previous years [4] - The skin care sector is the most sought-after, with 705,000 patients, accounting for 56.6% of total foreign medical visits [4] - The Korean medical beauty market was valued at $572.14 million in 2023 and is projected to grow to $1.14 billion by 2029, with a compound annual growth rate of 12.29% [6] Group 2: Consumer Behavior and Preferences - Many young consumers are opting for "medical beauty weekends," traveling to Korea for quick procedures due to the perceived cost-effectiveness and advanced technology [2][3] - The average cost of procedures in Korea is significantly lower than in China, with some treatments costing only one-third of the price in Japan [5][6] - The presence of multilingual staff and tailored services for foreign patients enhances the overall experience, making it easier for non-Korean speakers to navigate the process [2][3] Group 3: Challenges and Concerns - The recent decision to eliminate the 10% tax refund for foreign patients may lead to a decline in visitor numbers, as this was a key factor in attracting international clients [6][7] - There are safety concerns and potential pitfalls in the medical beauty industry, including price transparency issues and the risk of inadequate pre- and post-operative care [7][8] - The disparity in quality among medical institutions, with many high-quality services concentrated in specific areas like Gangnam, poses challenges for consumers seeking reliable treatments [7][8]